May 30, 2017 — The U.S. Food and Drug Administration today approved the first generic versions of Strattera (atomoxetine) to treat attention-deficit/hyperactivity disorder (ADHD) in pediatric and adult patients. Apotex Inc., Teva Pharmaceuticals…Original Article
FDA Approves First Generic Strattera for the Treatment of ADHD
